Phase 3 clinical development of semaglutide (2015-2026): a comprehensive evidence-based review of trial designs, therapeutic outcomes and global clinical experience
Study context
- Population
- Phase 3, Phase 3a, and Phase 3b clinical trials (CTs) assessing the efficacy, safety and therapeutic utility of semaglutide, with an emphasis on the SUSTAIN, PIONEER, STEP, SELECT, FLOW, SOUL and related programmes
- Outcome
- Efficacy
Main finding
As reported in the abstract
- Clinically meaningful improvements in glycaemic control and body weight, as well as cardiovascular and renal benefits, in selected populations
- Evidence from obesity and post-bariatric studies further supports its expanding therapeutic role beyond conventional glucose management
Further findings
- Differences in populations, treatment duration, comparators and endpoint definitions highlight important evidence gaps
Original publication
Phase 3 clinical development of semaglutide (2015-2026): a comprehensive evidence-based review of trial designs, therapeutic outcomes and global clinical experience. Diabetes Res Clin Pract. Published 7 November 2026. doi:10.
Composed by AI from the published abstract and checked against it. How Briefs are made →